aspirin has been researched along with Cell Transformation, Neoplastic in 42 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Cell Transformation, Neoplastic: Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
Excerpt | Relevance | Reference |
---|---|---|
"Despite being shown to be effective for chemoprevention of colorectal cancer, aspirin has limitations including adverse effects and inability to block colitis-associated colon cancer (CAC)." | 8.31 | Combining gamma-tocopherol and aspirin synergistically suppresses colitis-associated colon tumorigenesis and modulates the gut microbiota in mice, and inhibits the growth of human colon cancer cells. ( Jiang, Q; Jones-Hall, Y; Liu, KY; Nakatsu, CH; Wang, Q, 2023) |
"Aspirin is a chemopreventive agent for colorectal adenoma and cancer (CRC) that, like many drugs inclusive of chemotherapeutics, has been investigated for its effects on bacterial growth and virulence gene expression." | 8.02 | Aspirin Modulation of the Colorectal Cancer-Associated Microbe Fusobacterium nucleatum. ( Brennan, CA; Chan, AT; Drew, DA; Gallini Comeau, CA; Garrett, WS; Glickman, JN; Nakatsu, G; Schoen, RE, 2021) |
"Regular use of aspirin appears to reduce the risk of colorectal cancers that overexpress COX-2 but not the risk of colorectal cancers with weak or absent expression of COX-2." | 7.74 | Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. ( Chan, AT; Fuchs, CS; Ogino, S, 2007) |
"Chronic inflammation has long been considered critical in pancreatic carcinogenesis, and recently studies showed that some anti-inflammatory agents such as aspirin could potentially be used to attenuate pancreatic carcinogenesis." | 4.95 | Inflammation-Related Pancreatic Carcinogenesis: Mechanisms and Clinical Potentials in Advances. ( Dai, JJ; Jiang, MJ; Tian, L; Wang, XP, 2017) |
"Despite being shown to be effective for chemoprevention of colorectal cancer, aspirin has limitations including adverse effects and inability to block colitis-associated colon cancer (CAC)." | 4.31 | Combining gamma-tocopherol and aspirin synergistically suppresses colitis-associated colon tumorigenesis and modulates the gut microbiota in mice, and inhibits the growth of human colon cancer cells. ( Jiang, Q; Jones-Hall, Y; Liu, KY; Nakatsu, CH; Wang, Q, 2023) |
"Aspirin is a chemopreventive agent for colorectal adenoma and cancer (CRC) that, like many drugs inclusive of chemotherapeutics, has been investigated for its effects on bacterial growth and virulence gene expression." | 4.02 | Aspirin Modulation of the Colorectal Cancer-Associated Microbe Fusobacterium nucleatum. ( Brennan, CA; Chan, AT; Drew, DA; Gallini Comeau, CA; Garrett, WS; Glickman, JN; Nakatsu, G; Schoen, RE, 2021) |
"We identify an aspirin-induced upregulated lncRNA, OLA1P2, in human colorectal cancer." | 3.83 | The aspirin-induced long non-coding RNA OLA1P2 blocks phosphorylated STAT3 homodimer formation. ( Ben, Q; Chen, W; Guo, H; Li, M; Liu, J; Qu, Y; Wang, Y; Zhang, J, 2016) |
" The protective effects of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) for colorectal cancers in experimental and clinical studies are also demonstrated in this review." | 3.77 | [Oncogenesis humoral mechanisms regulation and NSAIDs ability in prevention of tumors]. ( Drozdov, VN; Kim, VA; Lazebnik, LV, 2011) |
"Regular use of aspirin appears to reduce the risk of colorectal cancers that overexpress COX-2 but not the risk of colorectal cancers with weak or absent expression of COX-2." | 3.74 | Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. ( Chan, AT; Fuchs, CS; Ogino, S, 2007) |
"Essential thrombocythemia is a chronic myeloproliferative neoplasm characterized by sustained thrombocytosis, bone marrow megakaryocytic hyperplasia and an increased risk of thrombosis and hemorrhage." | 2.49 | [Treatment of essential thrombocythemia]. ( Alvarez-Larrán, A; Besses, C; Cervantes, F, 2013) |
"Pancreatic cancer is the most deadly of all gastrointestinal malignancies with near zero five-year survival." | 2.43 | NF-kappaB, inflammation and pancreatic carcinogenesis: NF-kappaB as a chemoprevention target (review). ( Rigas, B; Zhang, Z, 2006) |
" An initial dosing study performed in healthy mice indicates that aspirin at a dose of 25 mg/kg/d has a similar pharmacodynamic effect as low-dose aspirin treatment in human subjects (100 mg/d)." | 1.56 | Effects of chronic low-dose aspirin treatment on tumor prevention in three mouse models of intestinal tumorigenesis. ( Hartung, NM; Kühl, AA; McDonald, FM; Ostermann, AI; Rohwer, N; Schebb, NH; Weylandt, KH; Zopf, D, 2020) |
" The two NSAIDs proved to be safe and efficacious in the experimental model used." | 1.43 | Selective inhibition by aspirin and naproxen of mainstream cigarette smoke-induced genotoxicity and lung tumors in female mice. ( Balansky, R; D'Oria, C; De Flora, S; Ganchev, G; Iltcheva, M; La Maestra, S; Micale, RT; Steele, VE, 2016) |
" We investigated the long-term administration of low dose of aspirin in a model of experimental colon carcinogenesis in rats." | 1.36 | Long-term administration of aspirin inhibits tumour formation and triggers anti-neoplastic molecular changes in a pre-clinical model of colon carcinogenesis. ( Bouhadjar, M; Bousserouel, S; Gosse, F; Marescaux, J; Raul, F; Soler, L, 2010) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 5 (11.90) | 18.7374 |
1990's | 3 (7.14) | 18.2507 |
2000's | 15 (35.71) | 29.6817 |
2010's | 14 (33.33) | 24.3611 |
2020's | 5 (11.90) | 2.80 |
Authors | Studies |
---|---|
Liu, KY | 1 |
Wang, Q | 1 |
Nakatsu, CH | 1 |
Jones-Hall, Y | 1 |
Jiang, Q | 1 |
Sun, L | 1 |
Suo, C | 1 |
Zhang, T | 1 |
Shen, S | 1 |
Gu, X | 1 |
Qiu, S | 1 |
Zhang, P | 1 |
Wei, H | 1 |
Ma, W | 1 |
Yan, R | 1 |
Chen, R | 1 |
Jia, W | 1 |
Cao, J | 1 |
Zhang, H | 1 |
Gao, P | 1 |
Rohwer, N | 1 |
Kühl, AA | 1 |
Ostermann, AI | 1 |
Hartung, NM | 1 |
Schebb, NH | 1 |
Zopf, D | 1 |
McDonald, FM | 1 |
Weylandt, KH | 1 |
Brennan, CA | 1 |
Nakatsu, G | 1 |
Gallini Comeau, CA | 1 |
Drew, DA | 1 |
Glickman, JN | 1 |
Schoen, RE | 1 |
Chan, AT | 2 |
Garrett, WS | 1 |
Feng, Y | 1 |
Tao, L | 1 |
Wang, G | 1 |
Li, Z | 1 |
Yang, M | 1 |
He, W | 1 |
Zhong, X | 1 |
Zhang, Y | 1 |
Yang, J | 1 |
Cheung, S | 1 |
McDonald, F | 1 |
Chen, L | 1 |
Dai, JJ | 1 |
Jiang, MJ | 1 |
Wang, XP | 1 |
Tian, L | 1 |
Bhardwaj, A | 1 |
Singh, H | 1 |
Trinidad, CM | 1 |
Albarracin, CT | 1 |
Hunt, KK | 1 |
Bedrosian, I | 1 |
Moeini, A | 1 |
Torrecilla, S | 1 |
Tovar, V | 1 |
Montironi, C | 1 |
Andreu-Oller, C | 1 |
Peix, J | 1 |
Higuera, M | 1 |
Pfister, D | 1 |
Ramadori, P | 1 |
Pinyol, R | 1 |
Solé, M | 1 |
Heikenwälder, M | 1 |
Friedman, SL | 1 |
Sia, D | 1 |
Llovet, JM | 1 |
Bain, BJ | 1 |
Garnett, C | 1 |
Deplano, S | 1 |
Naresh, K | 1 |
Kanfer, E | 1 |
Alvarez-Larrán, A | 1 |
Cervantes, F | 1 |
Besses, C | 1 |
Wang, R | 1 |
Wang, Y | 2 |
Gao, Z | 1 |
Qu, X | 1 |
Balansky, R | 1 |
Ganchev, G | 1 |
Iltcheva, M | 1 |
Micale, RT | 1 |
La Maestra, S | 1 |
D'Oria, C | 1 |
Steele, VE | 2 |
De Flora, S | 1 |
Guo, H | 1 |
Liu, J | 1 |
Ben, Q | 1 |
Qu, Y | 1 |
Li, M | 1 |
Chen, W | 1 |
Zhang, J | 1 |
Clouser, MC | 1 |
Roe, DJ | 1 |
Foote, JA | 1 |
Harris, RB | 1 |
Bousserouel, S | 1 |
Gosse, F | 2 |
Bouhadjar, M | 2 |
Soler, L | 2 |
Marescaux, J | 2 |
Raul, F | 2 |
Hsieh, CC | 1 |
Hernández-Ledesma, B | 1 |
de Lumen, BO | 1 |
Femia, AP | 1 |
Salvianti, F | 1 |
Luceri, C | 1 |
Dolara, P | 1 |
Salvadori, M | 1 |
Pinzani, P | 1 |
Caderni, G | 1 |
Maxwell, PH | 1 |
Kim, VA | 1 |
Lazebnik, LV | 1 |
Drozdov, VN | 1 |
Rao, CV | 1 |
Mohammed, A | 1 |
Janakiram, NB | 1 |
Li, Q | 1 |
Ritchie, RL | 1 |
Lightfoot, S | 1 |
Vibhudutta, A | 1 |
Caine, GJ | 1 |
Kehoe, ST | 1 |
Lip, GY | 1 |
Bair, WB | 1 |
Hart, N | 1 |
Einspahr, J | 1 |
Liu, G | 1 |
Dong, Z | 3 |
Alberts, D | 1 |
Bowden, GT | 1 |
Funk, JO | 1 |
Ghezzo, F | 1 |
Cesano, L | 1 |
Mognetti, B | 1 |
Pesce, E | 1 |
Pirro, E | 1 |
Corvetti, G | 1 |
Berta, GN | 1 |
Zingaro, B | 1 |
Di Carlo, F | 1 |
Ouyang, N | 1 |
Williams, JL | 1 |
Rigas, B | 2 |
Zhang, Z | 1 |
Moral, MA | 1 |
Khurdayan, VK | 1 |
Bozzo, J | 1 |
Ogino, S | 1 |
Fuchs, CS | 1 |
Markowitz, SD | 1 |
Osswald, AB | 1 |
Foltzer-Jourdainne, C | 1 |
Jiménez, P | 1 |
García, A | 1 |
Santander, S | 1 |
Piazuelo, E | 1 |
Mehta, P | 1 |
Grignani, G | 1 |
Pacchiarini, L | 1 |
Almasio, P | 1 |
Pagliarino, M | 1 |
Gamba, G | 1 |
Huang, C | 1 |
Brown, RE | 1 |
Ma, WY | 1 |
Morgan, G | 1 |
Goodsell, DS | 1 |
Shimamura, T | 1 |
Hsu, TC | 1 |
Colburn, NH | 1 |
Bejcek, BE | 1 |
Bode, AM | 1 |
Claesson, HE | 1 |
Lindgren, JA | 1 |
Hammarström, S | 1 |
St John, DJ | 1 |
Yeomans, ND | 1 |
Bourne, CA | 1 |
de Boer, WG | 1 |
Radner, BS | 1 |
Kennedy, AR | 1 |
Patierno, SR | 1 |
Lehman, NL | 1 |
Henderson, BE | 1 |
Landolph, JR | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
0822GCC Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients[NCT00771953] | Phase 2 | 109 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
For determining progression-free survival, progression was determined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0). Progression was defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00771953)
Timeframe: From the date of randomization until the first date that recurrent or progressive disease is objectively documented.
Intervention | days (Median) |
---|---|
Apricoxib Plus Docetaxel | 75 |
Placebo Plus Docetaxel | 97 |
Apricoxib Plus Pemetrexed | 103 |
Placebo Plus Pemetrexed | 98 |
7 reviews available for aspirin and Cell Transformation, Neoplastic
Article | Year |
---|---|
Inflammation-Related Pancreatic Carcinogenesis: Mechanisms and Clinical Potentials in Advances.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Transformation, Neoplastic; Humans; | 2017 |
[Treatment of essential thrombocythemia].
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Cell Transformation, Neoplastic; Disease Progress | 2013 |
NF-kappaB, inflammation and pancreatic carcinogenesis: NF-kappaB as a chemoprevention target (review).
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Aspirin; Cell Pr | 2006 |
Chronicles in drug discovery.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Budesonide; Cell | 2006 |
Prevention of cancer in the upper gastrointestinal tract with COX-inhibition. Still an option?
Topics: Adenocarcinoma; Anticarcinogenic Agents; Aspirin; Cardiovascular Diseases; Cell Transformation, Neop | 2007 |
Potential role of platelets in the pathogenesis of tumor metastasis.
Topics: Animals; Aspirin; Blood Platelets; Capillary Permeability; Cell Transformation, Neoplastic; Endothel | 1984 |
Signal transduction pathways: targets for chemoprevention of skin cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Cell Transformat | 2000 |
1 trial available for aspirin and Cell Transformation, Neoplastic
Article | Year |
---|---|
Effect of non-steroidal anti-inflammatory drugs on non-melanoma skin cancer incidence in the SKICAP-AK trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Arizona; Aspirin; Carcinoma, Basal | 2009 |
34 other studies available for aspirin and Cell Transformation, Neoplastic
Article | Year |
---|---|
Combining gamma-tocopherol and aspirin synergistically suppresses colitis-associated colon tumorigenesis and modulates the gut microbiota in mice, and inhibits the growth of human colon cancer cells.
Topics: Animals; Aspirin; Azoxymethane; Carcinogenesis; Cell Transformation, Neoplastic; Colitis; Colonic Ne | 2023 |
ENO1 promotes liver carcinogenesis through YAP1-dependent arachidonic acid metabolism.
Topics: Arachidonic Acid; Aspirin; Biomarkers, Tumor; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; | 2023 |
Effects of chronic low-dose aspirin treatment on tumor prevention in three mouse models of intestinal tumorigenesis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Azoxymethane; Carcinogens; Cel | 2020 |
Aspirin Modulation of the Colorectal Cancer-Associated Microbe Fusobacterium nucleatum.
Topics: Adenoma; Animals; Aspirin; Bacteria; Carcinogenesis; Cell Transformation, Neoplastic; Colon; Colorec | 2021 |
Aspirin inhibits prostaglandins to prevents colon tumor formation via down-regulating Wnt production.
Topics: Animals; Aspirin; Azoxymethane; Cell Transformation, Neoplastic; Colitis; Colitis-Associated Neoplas | 2021 |
The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer.
Topics: Animals; Aspirin; Biomarkers, Tumor; Biosynthetic Pathways; Cell Line, Tumor; Cell Transformation, N | 2018 |
An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents.
Topics: Animals; Anticarcinogenic Agents; Aspirin; Biomarkers, Tumor; Carcinoma, Hepatocellular; Case-Contro | 2019 |
Dysplasia of all granulocyte lineages in myelodysplastic evolution of essential thrombocythemia.
Topics: Aged; Amino Acid Substitution; Antineoplastic Agents; Aspirin; Bone Marrow; Cell Lineage; Cell Trans | 2013 |
The comparative study of acetyl-11-keto-beta-boswellic acid (AKBA) and aspirin in the prevention of intestinal adenomatous polyposis in APC(Min/+) mice.
Topics: Adenocarcinoma; Adenomatous Polyposis Coli; Administration, Oral; Animals; Anti-Inflammatory Agents; | 2014 |
Selective inhibition by aspirin and naproxen of mainstream cigarette smoke-induced genotoxicity and lung tumors in female mice.
Topics: Animals; Anticarcinogenic Agents; Aspirin; Cell Transformation, Neoplastic; Cyclooxygenase Inhibitor | 2016 |
The aspirin-induced long non-coding RNA OLA1P2 blocks phosphorylated STAT3 homodimer formation.
Topics: Animals; Apoptosis; Aspirin; Cell Line, Tumor; Cell Transformation, Neoplastic; Colorectal Neoplasms | 2016 |
Long-term administration of aspirin inhibits tumour formation and triggers anti-neoplastic molecular changes in a pre-clinical model of colon carcinogenesis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Azoxymethane; Carc | 2010 |
Lunasin-aspirin combination against NIH/3T3 cells transformation induced by chemical carcinogens.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Anacardic Acids; Animals; Anticarcinogenic Agents; Antineoplastic | 2011 |
Sustained proliferation and resistance to apoptosis after a cytotoxic insult are early alterations in rat colon carcinogenesis.
Topics: 1,2-Dimethylhydrazine; Animals; Apoptosis; Aspirin; bcl-2 Homologous Antagonist-Killer Protein; Biom | 2012 |
Tumor strengths and frailties: Aspiring to prevent colon cancer.
Topics: Aspirin; Cell Transformation, Neoplastic; Colonic Neoplasms; Colorectal Neoplasms, Hereditary Nonpol | 2012 |
[Oncogenesis humoral mechanisms regulation and NSAIDs ability in prevention of tumors].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Transformation, Neoplastic; Colorectal Neopla | 2011 |
Inhibition of pancreatic intraepithelial neoplasia progression to carcinoma by nitric oxide-releasing aspirin in p48(Cre/+)-LSL-Kras(G12D/+) mice.
Topics: Animals; Anticarcinogenic Agents; Aspirin; beta Catenin; Body Weight; Carcinoma in Situ; Carcinoma, | 2012 |
The role of aspirin in carcinogenesis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arylsulfotransferase; Aspirin; Carcinogens; Cell T | 2002 |
Inhibitory effects of sodium salicylate and acetylsalicylic acid on UVB-induced mouse skin carcinogenesis.
Topics: Administration, Topical; Animals; Anticarcinogenic Agents; Aspirin; Biopsy, Needle; Cell Transformat | 2002 |
[Aspirin against cylindromatosis? Molecular functions of the CYLD tumor suppressor].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Carcinoma, Adenoid Cystic; Cell Transfo | 2004 |
Salicylate inhibition of rat mammary carcinogenesis and angiogenesis in female rat compatible with misoprostol administration.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Transformation, Neoplastic; Disease | 2005 |
NO-donating aspirin isomers downregulate peroxisome proliferator-activated receptor (PPAR)delta expression in APC(min/+) mice proportionally to their tumor inhibitory effect: Implications for the role of PPARdelta in carcinogenesis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Cell Proliferation; Cell Trans | 2006 |
Aspirin and the risk of colorectal cancer in relation to the expression of COX-2.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Transformation, Neoplastic; Cohort Studies; C | 2007 |
Aspirin and colon cancer--targeting prevention?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Transformation, Neoplastic; Colorectal Neopla | 2007 |
Follow-up of tumor development in the colons of living rats and implications for chemoprevention trials: assessment of aspirin-difluoromethylornithine combination.
Topics: 1,2-Dimethylhydrazine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspi | 2007 |
Activation of platelet prostaglandin biosynthesis pathway during neoplastic cell-induced platelet aggregation.
Topics: Animals; Apyrase; Aspirin; Blood Platelets; Cell Line; Cell Transformation, Neoplastic; Fibrosarcoma | 1984 |
Inhibition of activator protein 1 activity and neoplastic transformation by aspirin.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aspirin; Calcium-Calmodulin-Depende | 1997 |
Correspondence re: R. Kim et al., Etiology of Barrett's metaplasia and esophageal adenocarcinoma. Cancer Epidemiol., Biomark. Prev., 6: 369-377, 1997.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Cell Transforma | 1998 |
The molecular perspective: cyclooxygenase-2.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Transformation, Neoplastic; Cyclooxygenase 2; | 2000 |
Activation of NF-kappaB is required for PDGF-B chain to transform NIH3T3 cells.
Topics: 3T3 Cells; Animals; Aspirin; Cell Transformation, Neoplastic; I-kappa B Proteins; Mice; Mutation; NF | 2002 |
Prostaglandin E2 production in 3T3 cells transformed by polyoma virus raises the intracellular adenosine 3':5'-monophosphate levels.
Topics: 5,8,11,14-Eicosatetraynoic Acid; Aspirin; Cell Line; Cell Transformation, Neoplastic; Cyclic AMP; In | 1977 |
Aspirin-induced glandular dysplasia of the stomach: histologic and histochemical studies in rats.
Topics: Animals; Aspirin; Cell Transformation, Neoplastic; Female; Gastric Mucosa; Pyloric Antrum; Rats; Sto | 1977 |
Suppression of x-ray induced transformation by Valium and aspirin in mouse C3H10T1/2 cells.
Topics: Animals; Aspirin; Cell Line; Cell Survival; Cell Transformation, Neoplastic; Diazepam; Dose-Response | 1990 |
Study of the ability of phenacetin, acetaminophen, and aspirin to induce cytotoxicity, mutation, and morphological transformation in C3H/10T1/2 clone 8 mouse embryo cells.
Topics: Acetaminophen; Animals; Aspirin; Biotransformation; Cell Survival; Cell Transformation, Neoplastic; | 1989 |